- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05645692
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
April 15, 2024 updated by: Hoffmann-La Roche
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy
This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
240
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Reference Study ID Number: BO44157 https://forpatients.roche.com/
- Phone Number: 888-662-6728
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia, 2109
- Recruiting
- Macquarie University Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5112
- Recruiting
- Lyell McEwin Hospital
-
Kurralta Park, South Australia, Australia, 5037
- Recruiting
- ICON Cancer Care Adelaide
-
-
-
-
PR
-
Curitiba, PR, Brazil, 80440-220
- Recruiting
- Hospital Universitario Evangelico De Curitiba
-
-
RJ
-
Rio de Janeiro, RJ, Brazil, 22250-905
- Recruiting
- Oncoclinicas Rio de Janeiro S.A.
-
-
RO
-
Porto Velho, RO, Brazil, 76834-899
- Recruiting
- Hospital de Amor Amazônia
-
-
RS
-
Porto Alegre, RS, Brazil, 90035-903
- Recruiting
- Hospital das Clinicas - UFRGS
-
-
SP
-
Santo André, SP, Brazil, 09060-650
- Recruiting
- *X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
-
Sao Paulo, SP, Brazil, 01323-903
- Recruiting
- Hospital Alemao Oswaldo Cruz
-
-
-
-
-
Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Beijing City, China, 100034
- Recruiting
- Peking University First Hospital
-
Chengdu City, China, 610047
- Active, not recruiting
- West China Hospital - Sichuan University
-
Guangzhou, China, 510060
- Recruiting
- Sun yat-sen University Cancer Center; Internal Medicine of Oncology
-
Shanghai, China, 200127
- Withdrawn
- Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
Shanghai City, China, 200025
- Recruiting
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Tianjin City, China, 300060
- Recruiting
- Tianjin Cancer Hospital; urologic tumor
-
Wuhan City, China, 430023
- Recruiting
- Union Hospital Tongji Medical College Huazhong University of science and Technology
-
-
-
-
-
Aalborg, Denmark, 9000
- Recruiting
- Aalborg Universitetshospital; Onkologisk Afdeling
-
Aarhus N, Denmark, 8200
- Recruiting
- Aarhus Universitetshospital; Kræftafdelingen
-
Herlev, Denmark, 2730
- Recruiting
- Herlev Hospital; Afdeling for Kræftbehandling
-
Odense C, Denmark, 5000
- Recruiting
- Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed
-
-
-
-
-
Besançon, France, 25030
- Recruiting
- CHRU Besançon
-
Bordeaux, France, 33075
- Recruiting
- CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre
-
Lyon CEDEX 08, France, 69373
- Recruiting
- Centre Léon Bérard
-
Montpellier, France, 34298
- Recruiting
- Institut Régional du Cancer de Montpellier
-
Rennes, France, 35000
- Recruiting
- Centre Eugène Marquis
-
Villejuif, France, 94805
- Recruiting
- Gustave Roussy
-
-
-
-
-
Düsseldorf, Germany, 40225
- Recruiting
- Universitätsklinikum Düsseldorf; Urologische Klinik
-
Halle (Saale), Germany, 06120
- Recruiting
- Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie
-
Hamburg, Germany, 20246
- Recruiting
- Martini-Klinik am UKE GmbH
-
Muenster, Germany, 48149
- Recruiting
- Universitaetsklinikum Muenster; Urology
-
Tübingen, Germany, 72076
- Recruiting
- Universitätsklinikum Tübingen; Klinik für Urologie
-
-
-
-
-
Athens, Greece, 115 28
- Recruiting
- Alexandras General Hospital of Athens; Oncology Department
-
Athens, Greece, 151 25
- Recruiting
- Athens Medical Center; Dept. of Oncology
-
Chaidari, Greece, 124 62
- Recruiting
- Attikon University General Hospital
-
Thessaloniki, Greece, 546 39
- Recruiting
- Theageneio Hospital
-
-
-
-
Campania
-
Napoli, Campania, Italy, 80131
- Active, not recruiting
- ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italy, 40138
- Active, not recruiting
- Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
-
Meldola, Emilia-Romagna, Italy, 47014
- Recruiting
- IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Recruiting
- Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica
-
-
Lombardia
-
Milano, Lombardia, Italy, 20132
- Recruiting
- IRCCS Ospedale San Raffaele
-
-
Puglia
-
Bari, Puglia, Italy, 70124
- Recruiting
- A.O. Universitaria Ospedale Consorziale Policlinico Di Bari; U.O. Oncologia Medica Universitaria
-
-
Umbria
-
Terni, Umbria, Italy, 05100
- Recruiting
- Azienda Ospedaliera S. Maria - Terni; Oncologia
-
-
Veneto
-
Padova, Veneto, Italy, 35128
- Recruiting
- IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
-
-
-
-
-
Gyeonggi-do, Korea, Republic of
- Recruiting
- Seoul National University Bundang Hospital; Internal Medicine
-
Incheon, Korea, Republic of, 21565
- Active, not recruiting
- Gachon University Gil Medical Center
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 05505
- Active, not recruiting
- Asan Medical Center
-
Seoul, Korea, Republic of, 06351
- Active, not recruiting
- Samsung Medical Center
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Severance Hospital, Yonsei University
-
-
-
-
Mexico CITY (federal District)
-
Cdmx, Mexico CITY (federal District), Mexico, 03100
- Recruiting
- Health Pharma Professional Research
-
Mexico City, Mexico CITY (federal District), Mexico, 14080
- Recruiting
- Instituto Nacional de Cancerologia
-
Mexico City, Mexico CITY (federal District), Mexico, 06720
- Recruiting
- Centro Medico Nacional Siglo Xxi - Imss; Hospital de Oncologia
-
-
-
-
-
Koszalin, Poland, 75-581
- Recruiting
- Szpital Wojewódzki im. Miko?aja Kopernika; Oddzia? Dzienny Chemioterapii
-
Kraków, Poland, 31-501
- Recruiting
- Szpital Uniwersytecki w Krakowie; Oddzial Kliniczny Onkologii i Poradnia Onkologiczna
-
Olsztyn, Poland, 10-228
- Recruiting
- ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii;Wojska Polskiego 37
-
Skórzewo, Poland, 60-185
- Recruiting
- Centrum Medyczne Pratia Poznan
-
Warszawa, Poland, 04-073
- Recruiting
- Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o.
-
-
-
-
-
Barcelona, Spain, 08908
- Recruiting
- Institut Catala d Oncologia Hospital Duran i Reynals
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre; Servicio de Oncologia
-
Madrid, Spain, 28050
- Recruiting
- HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
-
Madrid, Spain, 28046
- Recruiting
- Hospital Universitario La Paz; Servicio de Oncologia
-
Madrid, Spain, 28040
- Recruiting
- Hospital Universitario Clínico San Carlos; Servicio de Oncologia
-
-
Barcelona
-
Sant Andreu de La Barca, Barcelona, Spain, 08740
- Recruiting
- Hospital Univ Vall d'Hebron; Servicio de Oncologia
-
-
-
-
-
Adana, Turkey, 01220
- Recruiting
- Adana Baskent University Medical Faculty; Oncology
-
Ankara, Turkey, 06800
- Recruiting
- Ankara City Hospital; Oncology
-
Edirne, Turkey, 22030
- Active, not recruiting
- Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
-
Izmir, Turkey, 35101
- Recruiting
- Izmir Medical Point Hospital
-
Kadiköy, Turkey, 34722
- Recruiting
- Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
-
-
-
-
-
Edinburgh, United Kingdom, EH4 2XU
- Recruiting
- Western General Hospital; Clinical Oncology
-
London, United Kingdom, E1 2ES
- Recruiting
- Barts and the London NHS Trust
-
Preston, United Kingdom, PR2 9HT
- Recruiting
- Royal Preston Hosptial
-
Sutton, United Kingdom, SM2 5PT
- Recruiting
- Royal Marsden Hospital (Sutton)
-
-
-
-
Florida
-
Orlando, Florida, United States, 32804
- Recruiting
- Advent Health Orlando
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Cleveland Clinic
-
Columbus, Ohio, United States, 43219
- Recruiting
- SCRI Mark H. Zangmeister Center
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Recruiting
- Sarah Cannon Research Institute / Tennessee Oncology
-
Nashville, Tennessee, United States, 37203
- Active, not recruiting
- SCRI Oncology Partners
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center; Oncology
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Fred Hutchinson Cancer Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
- Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. Participants with squamous, sarcomatoid, micropapillary, and glandular variant histologies are eligible for inclusion in the study, provided that a urothelial component is present in the tumor specimen. Participants with other variant histologies or pure variant histologies are not eligible for inclusion in this study
- Ineligible ("unfit") to receive platinum-based chemotherapy
- No prior chemotherapy for inoperable locally advanced or metastatic or recurrent urothelial carcinoma (UC)
- Measurable disease; at least one measurable lesion as defined by response evaluation criteria in solid tumors, version 1.1 (RECIST v1.1)
- Availability of a representative leftover tumor specimen that is suitable for determination of PD-L1 status as assessed by a central laboratory
- Adequate hematologic and end organ function
- Negative for hepatitis B and hepatitis C virus (HCV)
- Adequate cardiovascular function
Exclusion Criteria:
- Pregnancy or breastfeeding
- GFR <15 mL/min/1.73 m2
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- History of leptomeningeal disease
- Uncontrolled tumor-related pain
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
- Uncontrolled or symptomatic hypercalcemia
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Active tuberculosis (TB) or acute Epstein-Barr virus (EBV)
- Significant cardiovascular/cerebrovascular disease within 3 months prior to initiation of study treatment
- Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
- History of another primary malignancy other than urothelial carcinoma within 2 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death
- Severe infection within 4 weeks prior to initiation of study treatment
- Treatment with therapeutic oral or intravenous antibiotics within 2 weeks prior to initiation of study treatment. Participants receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease [COPD] exacerbation), or who are receiving oral antibiotics to treat a urinary tract infection are eligible for the study
- Prior allogeneic stem cell or solid organ transplantation
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment or within 5 months after the final dose of atezolizumab, 4 months after the final dose of tobemstomig, or 90 days after the final dose of tiragolumab
- Current treatment with anti-viral therapy for HBV
- Treatment with any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
- Treatment with investigational therapy within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-TIGIT and anti-LAG3 therapeutic antibodies or pathways targeting agents
- Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives prior to initiation of study treatment
- Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment
- History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A
Participants will receive intravenous (IV) atezolizumab every 3 weeks (Q3W).
|
Participants will receive 1200 mg IV atezolizumab Q3W.
|
Experimental: Arm B
Participants will receive IV tobemstomig Q3W.
|
Participants will receive 600 mg IV tobemstomig Q3W.
Other Names:
|
Experimental: Arm C
Participants will receive IV tobemstomig + IV tiragolumab Q3W.
|
Participants will receive 600 mg IV tiragolumab Q3W.
Participants will receive 600 mg IV tobemstomig Q3W.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Confirmed Objective Response Rate (ORR)
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-Free Survival (PFS)
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Overall Survival (OS)
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Duration of Response (DOR)
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
PFS
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
OS
Time Frame: 6 months, 12 months, and 18 months
|
6 months, 12 months, and 18 months
|
Disease Control Rate (DCR)
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
Time to Confirmed Deterioration (TTCD)
Time Frame: Baseline up to 3 weeks
|
Baseline up to 3 weeks
|
Change from Baseline in European Organisation for Research and Cancer Treatment Item Library 187 (EORTC IL 187) Scores
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Maximum serum concentration (Cmax) of tiragolumab
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Minimum serum concentration (Cmin) of tiragolumab
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Cmax of atezolizumab
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Cmin of atezolizumab
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Incidence of Anti-Drug Antibodies (ADAs)
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Maximum Concentration (Cmax) of Tobemstomig
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Time of Maximum Concentration (Tmax) of Tobemstomig
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Clearance (CL) of Tobemstomig
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Volume of Distribution at Steady State (Vss) of Tobemstomig
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Area Under the Curve (AUC) of Tobemstomig
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Half-Life (T1/2) of Tobemstomig
Time Frame: Up to approximately 30 months
|
Up to approximately 30 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-LaRoche
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 13, 2023
Primary Completion (Estimated)
December 30, 2026
Study Completion (Estimated)
December 30, 2026
Study Registration Dates
First Submitted
November 28, 2022
First Submitted That Met QC Criteria
December 7, 2022
First Posted (Actual)
December 9, 2022
Study Record Updates
Last Update Posted (Actual)
April 16, 2024
Last Update Submitted That Met QC Criteria
April 15, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BO44157
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org).
Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Cancer
-
Spanish Oncology Genito-Urinary GroupBristol-Myers SquibbRecruiting
-
Astellas Pharma Global Development, Inc.Merck Sharp & Dohme LLC; Seagen Inc.RecruitingUrothelial CancerUnited States, Argentina, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, Thailand and more
-
Fundacion CRIS de Investigación para Vencer el...GlaxoSmithKline; Apices Soluciones S.L.; IpsenActive, not recruiting
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingUrothelial CancerGermany, Switzerland
-
University of ChicagoCompletedUrothelial CancerUnited States
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdActive, not recruitingUrothelial CancerRussian Federation, United States, Brazil, Spain, Chile, Korea, Republic of, Argentina, Australia, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Poland, Romania, Swed... and more
-
AstraZenecaActive, not recruitingUrothelial CancerUnited States, Belgium, Denmark, Germany, Italy, Spain, Canada, Poland, Taiwan, France, Korea, Republic of, Netherlands, United Kingdom, Brazil, Japan, Mexico, Russian Federation, Turkey, China, Austria, Australia, Israel, Portugal, G...
-
Canadian Cancer Trials GroupCelgene; Australian and New Zealand Urogenital and Prostate Cancer Trials GroupCompletedUrothelial CancerCanada, Australia
-
Janssen Research & Development, LLCActive, not recruitingUrothelial CancerKorea, Republic of, United States, Italy, Spain, Japan, United Kingdom, Belgium, Israel, China, Austria, France, Canada, Taiwan, Turkey, Germany, Russian Federation, Bulgaria, Poland, Greece, Brazil, Netherlands, Australia, Argentina, Mexic... and more
-
Janssen Research & Development, LLCActive, not recruitingUrothelial CancerUnited States, France, Germany, United Kingdom, Belgium, Taiwan, Spain, Israel, India, Romania, Korea, Republic of, Russian Federation, Turkey, Austria, Moldova, Republic of
Clinical Trials on Atezolizumab
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Intergroupe Francophone de Cancerologie ThoraciqueRoche Pharma AG; GFPCCompletedSmall Cell Lung CancerFrance
-
Yonsei UniversityNot yet recruitingNon-small Cell Lung CancerKorea, Republic of
-
Incyte CorporationHoffmann-La Roche; Genentech, Inc.TerminatedUC (Urothelial Cancer) | NSCLC (Non-small Cell Lung Carcinoma)United States
-
Corvus Pharmaceuticals, Inc.Genentech, Inc.CompletedRenal Cell Cancer | Metastatic Castration Resistant Prostate CancerUnited States, Canada, Australia
-
First Affiliated Hospital of Zhejiang UniversityHoffmann-La Roche; Geneplus-Beijing Co. Ltd.UnknownNon-Small Cell Lung CancerChina
-
Astellas Pharma Global Development, Inc.CompletedAcute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) MutationUnited States
-
The Netherlands Cancer InstituteRoche Pharma AGCompletedBreast Cancer | Ovarian Cancer | Cervix Cancer | Endometrial CancerNetherlands
-
Yale UniversityTerminatedAsymptomatic MyelomaUnited States
-
Chonnam National University HospitalRoche Pharma AGCompletedLung Neoplasm MalignantKorea, Republic of